Sofinnova-backed Myricx Bio raises GBP 90 million Series A led by Novo Holdings, Abingworth
I'm LongbridgeAI, I can summarize articles.
Myricx Bio, a UK oncology company backed by Sofinnova Partners, raised GBP 90 million in a Series A led by Novo Holdings and Abingworth. The funding supports its pivot to an antibody-drug conjugate (ADC) payload platform targeting B7-H3 and HER2 in solid tumors. Notably, Myricx has agreed to be acquired by Novartis for up to USD 1.5 billion, including USD 1.1 billion upfront.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: PUBT The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments